STOCK TITAN

Cidara Theraptcs - CDTX STOCK NEWS

Welcome to our dedicated page for Cidara Theraptcs news (Ticker: CDTX), a resource for investors and traders seeking the latest updates and insights on Cidara Theraptcs stock.

Company Overview

Cidara Therapeutics (CDTX) is an innovative biotechnology company focused on transforming the treatment paradigms for infectious diseases that have long been underserved by standard therapies. Through a multifaceted approach, the company develops novel immunotherapies and anti-infectives, leveraging its proprietary Cloudbreak® platform to engineer drug-Fc conjugates (DFCs) that uniquely combine targeted small molecules or peptides with a human antibody fragment. This integrated strategy allows Cidara to address complex infectious challenges including systemic fungal infections, vulvovaginal candidiasis, and seasonal as well as pandemic influenza among others.

Core Technologies and Business Model

At the heart of Cidara Therapeutics is its breakthrough Cloudbreak® platform, a versatile and cutting-edge technology designed to create single molecule cocktails with dual functionality. The platform enables the generation of DFCs that not only inhibit specific disease targets directly, but also engage the immune system, thereby potentially enhancing the overall efficacy of the treatment. The company’s approach spans several therapeutic areas, including anti-fungal and antiviral applications as well as oncologic and autoimmune indications, setting it apart in the competitive biotechnology landscape.

Pipeline and Product Candidates

Cidara’s product pipeline is strategically diversified to mitigate risk and maximize the clinical impact. The company is advancing multiple product candidates:

  • CD101 IV and CD101 Topical: These candidates target systemic fungal infections and vulvovaginal candidiasis, respectively, representing the first steps in introducing novel anti-fungal therapies with potential once-weekly or topical administration regimes.
  • CD388: As a long-acting antiviral DFC, CD388 is designed to provide universal prevention against influenza A and B by directly inhibiting viral proliferation. This candidate is engineered to function independently of the host immune response, offering potential advantages over traditional vaccines.
  • Cloudbreak-Facilitated Immunotherapies: In addition to its anti-infective portfolio, Cidara leverages its Cloudbreak platform to develop immunotherapeutic agents aimed at targeting oncologic, viral, and autoimmune diseases, broadening the company’s application footprint and research potential.

Market Position and Competitive Landscape

Cidara Therapeutics operates in a highly specialized niche within the biotechnology sector. By focusing on areas where current standard of care therapies fall short, the company positions itself as a catalyst for change in treatment protocols. Its use of innovative immunotherapeutic strategies, particularly the creation of DFCs via the Cloudbreak® platform, equips it with a unique competitive advantage. While facing challenges common to the biotechnology arena such as rigorous clinical validation and regulatory hurdles, CDTX differentiates itself through its precise and targeted approach, underpinned by robust partnerships and strategic asset optimization.

Operations and Clinical Development

The company’s operations are characterized by a dedicated focus on clinical research and development. Cidara’s scientific methodology emphasizes the identification and validation of molecular targets related to severe infectious diseases, followed by the development of therapies that harness the body’s own immune system. The approach includes detailed clinical investigations to assess safety, pharmacokinetics, and overall efficacy of its product candidates, ensuring that each development milestone reinforces the company’s technical credibility and commitment to patient safety.

Strategic Initiatives and Industry Impact

Cidara Therapeutics continuously refines its strategic focus through targeted asset divestitures and reacquisitions, ensuring that resources are effectively directed towards high-impact projects. The company’s ability to secure substantial investment through non-dilutive financing and private placements highlights its robust pipeline and commitment to clinical excellence. By concentrating on a subset of transformative treatment areas, Cidara is not only paving the way for new therapeutic options but also setting benchmarks in drug development methodologies that can serve as a model for the broader biotechnology community.

Research and Development Excellence

In a field that demands both precision and innovation, the expertise at Cidara Theraputics is demonstrated by its rigorous research protocols and validated data from early clinical studies. The company’s scientific leadership, supported by collaborative partnerships with industry leaders, has enabled the generation of compelling preclinical and clinical data. This multi-disciplinary approach ensures that all aspects of the product development process are optimized to maximize the potential for clinical success and long-term sustainability in the competitive healthcare market.

Conclusion

In summary, Cidara Therapeutics is a biotechnology innovator focused on delivering next-generation immunotherapies and anti-infectives that address critical unmet needs in infectious disease treatment. By combining state-of-the-art technologies with an integrated clinical development strategy, the company provides a comprehensive and nuanced approach to modern therapeutic challenges. Its ongoing commitment to scientific rigor, operational excellence, and strategic asset management underscores Cidara’s significant role in shaping the future landscape of modern medicine, while ensuring that the content remains informative and relevant for years to come.

Rhea-AI Summary
Cidara Therapeutics presents positive preclinical data on CD388, a drug-Fc conjugate candidate targeting influenza A and B, at the ISIRV conference. CD388 shows activity against seasonal and pandemic influenza strains, including neuraminidase-resistant strains. The company is advancing its Cloudbreak DFC program in a Phase 2a trial and is also developing an oncology DFC candidate, CD421.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) has announced the FDA approval of REZZAYO™ (rezafungin for injection), a novel once-weekly echinocandin for treating candidemia and invasive candidiasis. The company received a $20 million milestone payment from Melinta Therapeutics, which acquired U.S. commercialization rights for REZZAYO. This marks the first new echinocandin approved in over a decade, addressing urgent treatment needs. Cidara is also eligible for an additional $47 million in milestones from existing partnerships based on successful completion of planned activities. With a year-end cash balance of $32.7 million and additional funding, Cidara aims to extend its cash runway. The company continues advancing its drug-Fc conjugate programs in oncology and autoimmune indications, with positive data from a Phase 2a trial.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.31%
Tags
-
Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) announced that Jeffrey Stein, Ph.D., the President and CEO, will participate in two upcoming investor conferences. The first is the Cantor Fitzgerald Future of Oncology Virtual Symposium on April 3, 2023, at 11:00 am ET, where he will take part in a panel discussion. The second event is the 22nd Annual Needham Virtual Healthcare Conference on April 17, 2023, at 12:45 pm ET, featuring a presentation and one-on-one investor meetings. Cidara's presentation at the Needham Conference will be available on-demand, with a replay accessible for 90 days. The company focuses on long-acting therapeutics for serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.78%
Tags
conferences
Rhea-AI Summary

Cidara Therapeutics, Inc. (Nasdaq: CDTX) has announced significant developments in its financial results for the year ending December 31, 2022, and updated its product pipeline. The company achieved a revenue of $64.3 million, an increase from $49.6 million in 2021, aided by a $25.9 million milestone recognized in connection with Melinta Therapeutics. Cidara received FDA approval for rezafungin, marking the first new treatment for candidemia in over a decade, enabling a $20 million milestone payment. Additionally, Cidara raised $28.4 million through public offerings. The net loss narrowed to $29.8 million from $42.5 million in 2021, demonstrating improved financial health.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.74%
Tags
-
Rhea-AI Summary

REZZAYO, a novel echinocandin from Cidara Therapeutics, has received FDA approval for treating candidemia and invasive candidiasis in adults lacking alternative treatment options. This marks the first new echinocandin approval in over a decade. The approval is based on successful data from the ReSTORE Phase 3 trial, demonstrating non-inferiority to caspofungin. REZZAYO, administered once weekly, aims to simplify treatment for patients facing serious fungal infections. The drug is expected to be commercially available by summer 2023, with Melinta Therapeutics overseeing its launch in the U.S., leveraging their expertise in acute care settings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-24.74%
Tags
-
Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) recently presented preclinical data on its CD73-targeting drug-Fc conjugate, CBO-212, at the ESMO Targeted Anticancer Therapies Congress in Paris (March 6-8, 2023). This marks a significant advancement in their oncology efforts, showcasing the anti-tumor potential of CBO-212. The data highlighted its ability to inhibit both soluble and cell-anchored CD73, restore immune cell activation, and induce receptor internalization, leading to tumor reduction in mouse models. Cidara is also advancing a refined version, CD421, with lower immunogenic properties. The company is committed to developing long-acting therapeutics to enhance patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
Rhea-AI Summary

Cidara Therapeutics, Inc. (Nasdaq: CDTX) has successfully completed its separate underwritten public offerings, securing gross proceeds of approximately $19.5 million. This includes the sale of 11,086,000 shares of common stock and 286,000 shares of Series X Convertible Preferred Stock, with the underwriter fully exercising its option for an additional 1,446,000 shares. The offerings were executed under an effective shelf registration statement with the SEC. Funds raised are intended to advance Cidara's long-acting therapeutics portfolio, focused on improving care for serious diseases, including its lead antifungal candidate, rezafungin.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.42%
Tags
-
Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) announced the pricing of two separate public offerings totaling approximately $17.5 million. The company plans to offer 9,640,000 shares of common stock and 286,000 shares of Series X Convertible Preferred Stock, convertible into 2,860,000 shares of common stock. The offerings are expected to close around March 7, 2023. An additional 1,446,000 shares may be purchased by the underwriter within 30 days. Cantor Fitzgerald & Co. serves as the sole book-running manager. The offerings aim to enhance Cidara's financial position to support its therapeutic developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.09%
Tags
-
Rhea-AI Summary

Cidara Therapeutics (Nasdaq: CDTX) has announced concurrent underwritten public offerings of its common stock and Series X Convertible Preferred Stock. The offerings are independent and subject to customary closing conditions, with Cantor Fitzgerald & Co. as the sole book-running manager. The company has granted a 30-day option to the underwriter to purchase an additional 15% of the common shares. The offerings are made under a shelf registration statement effective with the SEC. Cidara is focused on long-acting therapeutics, particularly its lead Phase 3 antifungal candidate, rezafungin, and other innovations targeting serious diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-14.09%
Tags
Rhea-AI Summary

Cidara Therapeutics (NASDAQ: CDTX) reported favorable interim data from its Phase 2a trial of CD388, a potential long-acting antiviral for influenza. As of February 13, 2023, results show that a single 150 mg dose of CD388 significantly reduced influenza viral replication and infection rates compared to placebo, with 21.4% of CD388 recipients infected versus 50% in the placebo group. The drug was well tolerated, with no adverse events linked to it. The study is being conducted in collaboration with Janssen Pharmaceuticals, aiming for universal prevention of seasonal and pandemic influenza strains.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.8%
Tags

FAQ

What is the current stock price of Cidara Theraptcs (CDTX)?

The current stock price of Cidara Theraptcs (CDTX) is $18.92 as of April 1, 2025.

What is the market cap of Cidara Theraptcs (CDTX)?

The market cap of Cidara Theraptcs (CDTX) is approximately 207.6M.

What is the core focus of Cidara Therapeutics?

Cidara Therapeutics is focused on developing novel immunotherapies and anti-infectives using its proprietary Cloudbreak platform, which enables the creation of innovative drug-Fc conjugates for serious infectious diseases.

How does the Cloudbreak platform work?

The Cloudbreak platform is a proprietary technology that couples targeted small molecules or peptides with a human antibody fragment, creating drug-Fc conjugates that not only inhibit disease targets but also engage the immune system to enhance therapeutic effects.

What therapeutic areas does Cidara address?

Cidara Therapeutics addresses multiple areas including anti-fungal treatments, antiviral therapies for influenza, oncology, and autoimmune diseases, focusing on conditions that are underserved by existing standard of care therapies.

What are some of the key product candidates in Cidara's pipeline?

Key candidates include CD101 IV and CD101 Topical for fungal infections, as well as CD388, a long-acting antiviral designed to provide universal prevention against influenza, along with additional DFC immunotherapies under development.

How does Cidara differentiate itself in the competitive biotech landscape?

Cidara differentiates itself through its innovative approach utilizing the Cloudbreak platform to develop drug-Fc conjugates, strategic asset management including divestitures and reacquisitions, and a focus on unmet medical needs across multiple therapeutic areas.

What is the significance of CD388?

CD388 is a long-acting antiviral candidate developed as part of the Cloudbreak platform, designed to offer universal protection against influenza strains through a single-dose administration, independent of the patient’s immune response.

How does Cidara ensure the safety and efficacy of its product candidates?

Cidara employs rigorous clinical research protocols that include extensive safety, pharmacokinetic, and efficacy assessments. This systematic approach, combined with validated preclinical and clinical data, supports its commitment to patient safety and therapeutic excellence.

Who are the typical partners and investors involved with Cidara Therapeutics?

Cidara works with a range of strategic partners, including major pharmaceutical companies and leading investors from the life sciences sector, which aids in advancing its clinical development programs and broadening its market impact.
Cidara Theraptcs

Nasdaq:CDTX

CDTX Rankings

CDTX Stock Data

207.57M
10.81M
1.38%
69.43%
2.17%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
SAN DIEGO